

Drug and Therapeutics Committee – Minutes – Approved

Date / Time	12 th February 2015
Venue	The Committee Room, Alderson House, HRI
Chair	Prof A Morice, Chair, Professor of Respiratory Medicine
Notes / Action Points	Mrs Wendy Hornsby, Senior Pharmacy Technician.
Quorate: Yes / No	Yes

Attendance	Mr S Gaines, Professional Secretary, Senior Principal Pharmacist – Clinical Services Mr P O'Brien, Deputy Chief Pharmacist Mrs C Grantham, Medicines Management Nurse Mr D Corral, Chief Pharmacist, Clinical Director Therapy & Therapeutics Mrs J Lyon, Head of Medicines Management, North Yorks and Humber CSU Mrs K Beal, Lay Trust Member Dr L Witvliet, GP Prescribing Lead, Hull CCG Prof M Lind, Vice Chair, Professor of Oncology Dr E Williamson, Consultant Microbiologist Dr H Klonin, Consultant Paediatrician
-------------------	---

Apologies	Dr A Harley, GP Prescribing Lead, ERY CCG
------------------	---

Agenda No	Item	Discussion	Decision Made	Action	Lead	Due Date	Progress /Date Closed
2015.02.02	Apologies	As above.					
2015.02.02	Declarations of Interest	There were no declarations of interest	Noted	No further action			2/15
2015.02.03	Minutes of the previous meeting	The minutes were accepted as a true record.	Accepted				2/15
2015.02.04	Action Tracker	<p>AOB Formulary has been updated in line with Royal College guidelines on poisoning.</p> <p>Action Tracker Botulinum meeting has taken place. New pricing framework is due to be released in March. Discuss further at next meeting.</p> <p>Action Tracker Nalmefene has been added to formulary for continuation of treatment only.</p> <p>Action Tracker ML has written to CSU regarding AREDS and Eflornithine.</p> <p>New Product Request AM has written to applicant and WH has updated formulary.</p>	<p>Action complete</p> <p>Action complete</p> <p>Action complete</p> <p>Action complete</p> <p>Action complete</p>				<p>2/15</p> <p>2/15</p> <p>2/15</p> <p>2/15</p> <p>2/15</p>

Agenda No	Item	Discussion	Decision Made	Action	Lead	Due Date	Progress /Date Closed
		NICE Guidance CG131 Oxaliplatin has been added to formulary	Action complete				2/15
		NICE Guidance CG191 Pneumonia Meeting of ACAT has not taken place therefore still to feedback.	Ongoing		SG	4/15	
		NICE Guidance WH has amended formulary to state "use in line with NICE Guidance" for NOACs.	Action complete				2/15
		MHRA DSU December 14 Surgery governance meeting to take place on 26/2/15, where SG will raise HES.	Ongoing		SG	3/15	
		Correspondence Received POB to feedback on radiology tender	Ongoing		POB	3/15	
		Correspondence Received Evicel has been added to formulary	Action complete		WH		2/15
		Chairs Approvals Eculizumab - DC talked through the paper about the renal transplant patient who was recently treated. NHSE initially would not fund the IFR, but have now agreed funding for this patient.	Action complete		DC		2/15
2015.02.05	New Product Requests	Peginterferon beta-1a (Plegridy) Approved on the basis of safety & efficacy, however not yet commissioned by NHSE. Would only be available at present via IFR, until commissioned.	Approved subject to IFR approval	AM to write to applicant WH to update formulary	AM/WH	3/15	
		Fentanyl pectin nasal spray (Pecfent) The committee felt the product was safe &	Deferred	SG to write to	SG	3/15	

Agenda No	Item	Discussion	Decision Made	Action	Lead	Due Date	Progress /Date Closed
		<p>effective, but more information was required about when the product would be used and in which patients.</p> <p>Dolutegravir and Dolutegravir/Abacavir/Lamivudine (Triumeq) This request had not been circulated to committee members but was raised by POB as the medicines are part of the NHSE HIV commissioning pathway that HEY follows.</p>	The committee agreed to give interim approval for the patients already lined up for treatment.	<p>applicant and request further information.</p> <p>SG to circulate new product request & commissioning papers before next meeting, with a view to adding to the formulary at the next meeting</p>	SG	3/15	
2015.02.06	NICE Guidance	<p>January 2015</p> <ul style="list-style-type: none"> HST1 Eculizumab for treating atypical haemolytic uraemic syndrome Drug recently requested on chairs approval for patient with post-renal transplant Haemolytic Uremic Syndrome (HUS). Prof Morice gave chairs approval for this transplant-threatening condition but issues over funding have occurred and need to be resolved for future high cost occurrences. NG1 Gastro oesophageal reflux disease: recognition, diagnosis and management in children and young people HEY Paediatric Pharmacist had already written local guidance in line with this, following MHRA alert on domperidone. 	<p>Finance representative to be invited to next D&T to discuss further New product request due on March agenda</p> <p>HK to check guidance is available in paediatric areas.</p>	<p>SG to invite finance to next meeting</p> <p>HK to feed back next time</p>	<p>SG</p> <p>HK</p>	<p>3/15</p> <p>3/15</p>	
2015.02.07	MHRA Drug Safety update	<p>January 2015 Content has now moved from MHRA website</p>	AM to write to	AM to write to	AM	3/15	

Agenda No	Item	Discussion	Decision Made	Action	Lead	Due Date	Progress /Date Closed
		to gov.uk website, with no PDF file available currently. Contents noted.	Rheumatology & Renal teams to highlight issues with mycophenolate	relevant teams			
2015.02.08	Minutes from the Safe Medication Practice Committee	January 2015 Minutes were draft version. <ul style="list-style-type: none"> • HEY are not changing the way we handle tramadol • Lorenzo to be trialled in Cardiology • Medicines management process in discharge lounge - review ongoing 	Noted	No further action			2/15
2015.02.09	Minutes from the Hull and East Riding Prescribing Committee	November 2014 JLy raised the issue of ezetimibe prescribing which has noticeably increased following a local promotional event. Prof Kilpatrick is currently updating the local guidelines.	JLy to feed back information on patient treatment requests in primary care to AM.	AM to write to Cardiology, when evidence is provided	JLy AM	3/15 4/15	
2015.02.10	Correspondence Received	None.					2/15
2015.02.11	Chairs Approvals	Eculizumab – Haemolytic Uremic Syndrome (HUS) – Dr M Chanayireh Bedaquiline – Multi drug resistant TB – Dr K Adams	Noted Noted	No further action No further action			2/15 2/15
2015.02.13	Issues to escalate to Clinical Quality Committee	None.	No further action				2/15

Agenda No	Item	Discussion	Decision Made	Action	Lead	Due Date	Progress /Date Closed
2015.02.14	Any other Business	<p>Octreotide – profuse bronchorrhea – Prof A Morice AM has written a paper for presentation at the next D&TC meeting. POB informed the committee that there are currently supply issues with octreotide injection and no date for when this issue will be resolved.</p> <p>DC raised the wording of the drug policy for the prescribing of chemotherapy.</p>	<p>Paper to be discussed at D&T in March</p> <p>The wording still needed to be agreed</p>	<p>SG to circulate for March D&TC</p> <p>ML to raise with chemo committee and DC to forward to SG for March D&TC</p>	<p>SG</p> <p>ML/DC</p>	<p>3/15</p> <p>3/15</p>	
2015.02.15	Date and Time of Next Meeting	<p>Thursday 12th March 2015, 8.15am – 9.30am. Committee Room, Alderson House, HRI</p>					